RxDoctor Payments Data

Maddie Jans, PA

Physician Assistant · Sioux Falls, SDNPI 1942741277

Payments from drug & device makers

$2,045in general payments, 2019–2025

Across 50 payments — averaging $40.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$1K
  • AbbVie$124
  • Neurocrine Biosciences, Inc.$120
  • AstraZeneca$85
  • Genentech USA, Inc.$85
  • Pfizer$62
  • plus $324 from 15 others

What the payments were for

  • Travel & lodging$72936%
  • Food & beverage$1,31564%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,045 in reported general payments places this provider in the 85th percentile of 548 physician assistant providers in South Dakota.

See all physician assistant providers in South Dakota

Medicare billing

Part B allowed, 2024
$41,636
Medicare patients
373
Services billed
807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex (4 Pack)Interferon Beta-1a11$89,420
Emgality PenGalcanezumab-Gnlm86$62,844
Nurtec OdtRimegepant Sulfate42$54,097
UbrelvyUbrogepant32$35,060
TopamaxTopiramate24$19,769
ZavzpretZavegepant Hcl19$19,469
FycompaPerampanel21$15,665
Lacosamide115$13,732
QuliptaAtogepant13$13,264
Levetiracetam472$13,096
NeuproRotigotine14$11,070
Carbidopa-LevodopaCarbidopa/Levodopa371$10,425
Aimovig AutoinjectorErenumab-Aooe14$10,074
Pyridostigmine Bromide56$6,196
Gabapentin268$4,115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Zavzpret, Dilantin$62$75,00873 claims
AbbVieUbrelvy, Qulipta$124$48,32445 claims
Eisai Inc.Fycompa$15$15,66521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 548 physician assistant providers in South Dakota.

Other physician assistant in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →